GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Cyclically Adjusted FCF per Share

CRISPR Therapeutics AG (MEX:CRSP) Cyclically Adjusted FCF per Share : MXN-37.82 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted free cash flow per share for the three months ended in Mar. 2025 was MXN-12.891. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-37.82 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-25), CRISPR Therapeutics AG's current stock price is MXN727.07. CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN-37.82. CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF of today is .


CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CRISPR Therapeutics AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -37.82

Competitive Comparison of CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted Price-to-FCF falls into.


;
;

CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-12.891/107.7224*107.7224
=-12.891

Current CPI (Mar. 2025) = 107.7224.

CRISPR Therapeutics AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 100.704 0.000
201509 -3.381 99.785 -3.650
201512 40.203 99.386 43.575
201603 -6.020 99.475 -6.519
201606 -6.817 100.088 -7.337
201609 -6.706 99.604 -7.253
201612 -8.925 99.380 -9.674
201703 -12.653 100.040 -13.625
201706 -7.839 100.285 -8.420
201709 -8.539 100.254 -9.175
201712 -7.294 100.213 -7.841
201803 -9.204 100.836 -9.833
201806 -10.797 101.435 -11.466
201809 -8.154 101.246 -8.676
201812 -11.149 100.906 -11.902
201903 -16.695 101.571 -17.706
201906 -13.925 102.044 -14.700
201909 44.886 101.396 47.687
201912 0.759 101.063 0.809
202003 -21.258 101.048 -22.662
202006 -12.358 100.743 -13.214
202009 -25.581 100.585 -27.396
202012 -24.391 100.241 -26.211
202103 -29.348 100.800 -31.364
202106 192.640 101.352 204.748
202109 -31.906 101.533 -33.851
202112 -24.445 101.776 -25.873
202203 -38.890 103.205 -40.592
202206 -39.343 104.783 -40.447
202209 -28.678 104.835 -29.468
202212 -29.743 104.666 -30.611
202303 1.315 106.245 1.333
202306 -29.978 106.576 -30.301
202309 -9.426 106.570 -9.528
202312 -20.620 106.461 -20.864
202403 22.122 107.355 22.198
202406 -20.773 107.991 -20.721
202409 -24.749 107.468 -24.808
202412 -12.270 107.128 -12.338
202503 -12.891 107.722 -12.891

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


CRISPR Therapeutics AG  (MEX:CRSP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CRISPR Therapeutics AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

Industry
Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.